Table 1.
Characteristics of the study population
| HLA-DR/DQ match group
|
||||
|---|---|---|---|---|
| Group 1 | Group 2 | Group 3 | Group 4 | |
| DRB1 matched | DRB1 matched | DRB1 mismatched | DRB1 mismatched | |
| DQB1 matched | DQB1 mismatched | DQB1 matched | DQB1 mismatched | |
| Number of pairs (%) | 335 (74) | 41 (9) | 48 (11) | 25 (6) |
| Transplant year, no. (%) | ||||
| 1987–1989 | 56 (17) | 9 (22) | 9 (19) | 0 |
| 1990–1992 | 157 (47) | 19 (46) | 22 (46) | 15 (60) |
| 1993–1995 | 121 (36) | 13 (32) | 17 (35) | 10 (40) |
| Mean patient age, no. (range) | 32 (0-55) | 31 (1-49) | 26 (1-50) | 24 (0-43) |
| 0–20 yr | 65 (19) | 8 (20) | 16 (33) | 8 (32) |
| 21–35 yr | 105 (31) | 16 (39) | 21 (44) | 13 (52) |
| >36 yr | 165 (49) | 17 (41) | 11 (23) | 4 (16) |
| Mean donor age, yr (range) | 37 (19-57) | 39 (22-53) | 39 (20-51) | 35 (18-48) |
| Patient/donor gender, no.(%) | ||||
| M/M | 120 (36) | 10 (24) | 20 (42) | 8 (32) |
| F/F | 61 (18) | 10 (24) | 8 (17) | 5 (20) |
| M/F | 70 (21) | 10 (24) | 10 (21) | 8 (32) |
| F/M | 84 (25) | 11 (27) | 10 (21) | 4 (16) |
| Female donor parity, no. (%) | ||||
| Yes | 85 (65) | 12 (60) | 13 (72) | 7 (54) |
| No | 40 (31) | 8 (40) | 4 (22) | 6 (46) |
| Unknown | 6 (5) | 0 | 1 (6) | 0 |
| Diagnosis, no. (%) | ||||
| Acute leukemia | ||||
| Rem | 43 (13) | 3 (7) | 10 (21) | 7 (28) |
| Rel | 60 (18) | 7 (17) | 12 (25) | 3 (12) |
| De novo | 1 (1) | 0 | 0 | 0 |
| Unknown | 1 (1) | 0 | 0 | 0 |
| Chronic leukemia | ||||
| CP | 138 (41) | 19 (46) | 12 (25) | 6 (24) |
| AP | 44 (13) | 5 (12) | 6 (13) | 0 |
| BC | 18 (5) | 3 (7) | 4 (8) | 3 (12) |
| BC/rem | 14 (4) | 1 (2) | 1 (2) | 2 (8) |
| Juv | 1 (1) | 0 | 2 (4) | 0 |
| MDS | 6 (2) | 3 (7) | 0 | 4 (16) |
| Lymphoma | ||||
| Rem | 1 (1) | 0 | 0 | 0 |
| Rel | 8 (2) | 0 | 1 (2) | 0 |
| TBI exposure, no. (%) | ||||
| 12 Gy | 133 (40) | 19 (46) | 9 (19) | 0 |
| 13.2 Gy | 151 (45) | 14 (34) | 26 (54) | 20 (80) |
| >13.2 Gy | 51 (15) | 8 (20) | 13 (27) | 5 (20) |
| Patient/donor CMV serostatus, no. (%) | ||||
| −/− | 127 (38) | 15 (37) | 14 (29) | 4 (16) |
| −/+ | 45 (13) | 6 (15) | 6 (13) | 6 (24) |
| +/− | 100 (30) | 11 (27) | 17 (35) | 9 (36) |
| +/+ | 63 (19) | 9 (22) | 11 (23) | 6 (24) |
| MTX compliance,* no. (%) | ||||
| Day 1 | 320/325 (98) | 39/41 (95) | 42/47 (89) | 23/24 (96) |
| Day 3 | 313/325 (96) | 40/41 (98) | 45/47 (96) | 23/24 (96) |
| Day 6 | 292/315 (93) | 38/40 (95) | 42/47 (89) | 23/24 (96) |
| Day 11 | 224/276 (81) | 27/32 (84) | 29/38 (76) | 17/20 (85) |
| CSP compliance,* no. (%) | ||||
| Week 1 | 277/326 (85) | 35/40 (88) | 41/47 (87) | 23/24 (96) |
| Week 2 | 215/274 (78) | 26/30 (87) | 27/36 (75) | 14/18 (78) |
| Week 3 | 145/218 (67) | 16/21 (76) | 17/30 (57) | 8/10 (80) |
| Week 4 | 130/200 (65) | 12/18 (67) | 18/26 (69) | 8/9 (89) |
| Week 5 | 114/194 (59) | 13/17 (76) | 15/24 (63) | 6/8 (75) |
Rem, remission; Rel, relapse; CP, chronic phase; AP, accelerated phase; BC, blast crisis; BC/rem, remission following initial BC; Juv, juvenile; MDS, myelodysplastic syndrome; MTX, methotrexate; CSP, cyclosporine; CMV, cytomegalovirus.
*
MTX and CSP compliance denotes the number of patients who received at least 80% of the recommended dose among patients at risk for acute GVHD (alive without acute GVHD, relapse, death, or second transplant).